LCI
$6.39
Lannett CO
$.11
1.75%
LCI
Earnings Whisper ®
N/A
2nd Quarter December 2020
Consensus:  $0.08
Revenue:  $135.78 Mil
Wednesday
Feb 3
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LCI reports earnings?
Beat
Meet
Miss

Where is LCI's stock price going from here?
Up
Flat
Down
Stock chart of LCI
Analysts
Summary of analysts' recommendations for LCI
Score
Grade
Pivots
Resistance
$6.67
$6.54
$6.47

$6.34

Support
$6.26
$6.13
$6.06
Tweet
Growth
Description
Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly